Herter, S., Herting, F., Muth, G., van Puijenbroek, E., Schlothauer, T., Ferrara, C., . . . Klein, C. (2018). GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. Haematologica.
Chicago Stili AlıntıHerter, Sylvia, et al. "GA101 P329GLALA, a Variant of Obinutuzumab With Abolished ADCC, ADCP and CDC Function but Retained Cell Death Induction, Is As Efficient As Rituximab in B-cell Depletion and Antitumor Activity." Haematologica 2018.
MLA AlıntıHerter, Sylvia, et al. "GA101 P329GLALA, a Variant of Obinutuzumab With Abolished ADCC, ADCP and CDC Function but Retained Cell Death Induction, Is As Efficient As Rituximab in B-cell Depletion and Antitumor Activity." Haematologica 2018.